Advertisement
New Zealand markets close in 6 hours 1 minute
  • NZX 50

    12,532.79
    -64.08 (-0.51%)
     
  • NZD/USD

    0.6129
    -0.0031 (-0.51%)
     
  • ALL ORDS

    8,479.00
    +62.40 (+0.74%)
     
  • OIL

    77.29
    +0.15 (+0.19%)
     
  • GOLD

    2,661.90
    -5.90 (-0.22%)
     

3 Growth Companies With High Insider Ownership On SEHK

The Hong Kong stock market has recently experienced fluctuations, with the Hang Seng Index seeing slight declines amid broader global economic concerns. Despite these challenges, growth companies with high insider ownership continue to attract investor interest due to their potential for robust performance and alignment of interests between management and shareholders. In this article, we will explore three such growth companies listed on the SEHK that demonstrate high insider ownership, offering insights into why they stand out in today's market environment.

Top 10 Growth Companies With High Insider Ownership In Hong Kong

Name

Insider Ownership

Earnings Growth

Laopu Gold (SEHK:6181)

36.4%

34.7%

Akeso (SEHK:9926)

20.5%

54.7%

Fenbi (SEHK:2469)

33%

22.4%

Zylox-Tonbridge Medical Technology (SEHK:2190)

18.8%

69.8%

Pacific Textiles Holdings (SEHK:1382)

11.2%

37.7%

Zhejiang Leapmotor Technology (SEHK:9863)

14.7%

78.9%

DPC Dash (SEHK:1405)

38.2%

104.2%

Beijing Airdoc Technology (SEHK:2251)

29.1%

93.4%

Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)

13.9%

109.2%

MicroTech Medical (Hangzhou) (SEHK:2235)

25.8%

105%

Click here to see the full list of 46 stocks from our Fast Growing SEHK Companies With High Insider Ownership screener.

Underneath we present a selection of stocks filtered out by our screen.

Meituan

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Meituan is a technology retail company operating in the People’s Republic of China with a market cap of approximately HK$744.92 billion.

Operations: Meituan's revenue segments include New Initiatives generating CN¥77.56 billion and Core Local Commerce contributing CN¥228.13 billion.

Insider Ownership: 11.6%

Revenue Growth Forecast: 12.9% p.a.

Meituan's earnings are forecast to grow significantly at 25.8% per year, outpacing the Hong Kong market's average growth rate. The company's revenue is expected to increase by 12.9% annually, also above the market average of 7.3%. Recent financials show a strong performance with half-year sales rising to CNY 155.53 billion and net income doubling from last year to CNY 16.72 billion. Insider ownership remains high, complemented by substantial share buybacks totaling HKD 7.17 billion this year.

SEHK:3690 Ownership Breakdown as at Sep 2024
SEHK:3690 Ownership Breakdown as at Sep 2024

Vobile Group

Simply Wall St Growth Rating: ★★★★★☆

Overview: Vobile Group Limited provides software as a service for digital content assets protection and transactions across the United States, Japan, Mainland China, and internationally, with a market cap of HK$3.32 billion.

Operations: The company generates revenue primarily from its SaaS offerings, amounting to HK$2.18 billion.

Insider Ownership: 23.2%

Revenue Growth Forecast: 21.4% p.a.

Vobile Group's earnings are forecast to grow significantly at 59.4% per year, surpassing the Hong Kong market's average growth rate. Revenue is expected to increase by 21.4% annually, also above the market average of 7.3%. Recent financials show half-year sales rising to HK$1.18 billion and net income increasing to HK$41.47 million from last year’s HK$29.16 million, though profit margins have decreased slightly over the past year.

SEHK:3738 Earnings and Revenue Growth as at Sep 2024
SEHK:3738 Earnings and Revenue Growth as at Sep 2024

Akeso

Simply Wall St Growth Rating: ★★★★★★

Overview: Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs with a market cap of HK$53.38 billion.

Operations: The company's revenue from the research, development, production, and sale of biopharmaceutical products is CN¥1.87 billion.

Insider Ownership: 20.5%

Revenue Growth Forecast: 33.1% p.a.

Akeso is expected to become profitable within three years, with revenue forecasted to grow at 33.1% annually, significantly outpacing the Hong Kong market. Despite recent financial challenges, including a net loss of CNY 238.59 million for H1 2024 and shareholder dilution over the past year, Akeso's innovative drug developments like ivonescimab show promise. Trading at 53.5% below estimated fair value and high insider ownership further underscore its growth potential in the biopharmaceutical sector.

SEHK:9926 Earnings and Revenue Growth as at Sep 2024
SEHK:9926 Earnings and Revenue Growth as at Sep 2024

Turning Ideas Into Actions

Want To Explore Some Alternatives?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include SEHK:3690 SEHK:3738 and SEHK:9926.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com